Ovarian hyperstimulation by LH leads to mammary gland hyperplasia and cancer predisposition in transgenic mice

Endocrinology

Volumn 143, Issue 9, 2002, Pages 3671-3680

  Milliken, Erin L ^a   Ameduri, Rebecca K ^a   Landis, Melissa D ^a   Behrooz, Alireza ^a   Abdul Karim, Fadi W ^a   Keri, Ruth A ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; CARCINOGEN; LUTEINIZING HORMONE; PROGESTERONE RECEPTOR; RNA;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST HYPERPLASIA; CANCER SUSCEPTIBILITY; CHEMICAL CARCINOGENESIS; FEMALE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OVARIECTOMY; OVARY HYPERSTIMULATION; PHENOTYPE; PREGNANCY; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; FEMALE; GENE EXPRESSION; HYPERPLASIA; LUTEINIZING HORMONE; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; MILK PROTEINS; OVARY; PHENOTYPE; PREGNANCY; RECEPTORS, PROGESTERONE; RISK FACTORS;

EID: 0036720732     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2002-220228     Document Type: Article

References (69)

1. Think globally, act locally: The making of a mouse mammary gland
2. Assessing the risk of breast cancer
3. Reproductive factors in breast cancer epidemiology
4. Does early physical maturity influence breast cancer risk?
5. Association of breast cancer risk with age at first and subsequent births: A study in the population of the Estonian Republic
6. The risk of breast cancer following reproductive surgery
7. Menstrual factors and breast cancer risk
8. Hormonal prevention of breast cancer: Mimicking the protective effect of pregnancy
9. Differentiation and breast cancer
10. Refractoriness to mammary tumorigenesis in parous rats: Is it caused by persistent changes in the hormonal environment or permanent biochemical alterations in the mammary epithelia?
11. Tamoxifen for early breast cancer: An overview of the randomised trials
12. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
13. The comparative pathology of human and mouse mammary glands
14. MMTV-induced mammary tumorigenesis: Gene discovery, progression to malignancy and cellular pathways
15. Chemical effects in transgenic mice bearing oncogenes expressed in mammary tissue
16. Differential regulation of cell cycle characteristics and apoptosis in MMTV-myc and MMTV-ras mouse mammary tumors
17. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
18. Role of endocrine, autocrine, and paracrine interactions in the development of mammary hyperplasia in Wnt-1 transgenic mice
19. Lack of growth of a pregnancy-dependent mouse mammary tumor (TPDMT-4) in the absence of pituitary hormones
20. Inhibited growth in vivo of a mouse pregnancy-dependent mammary tumor (TPDMT-4) by an antiestrogen, 2α, 3α-epithio-5α-androstan-17β-ol (10275-S)
21. Pituitary-isografted mice are highly susceptible to MNU-induced mammary carcinogenesis irrespective of the level of alveolar differentiation
22. Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice
23. Presence of functional luteinizing hormone/chorionic gonadotropin (hCG) receptors in human breast cell lines: Implications supporting the premise that hCG protects women against breast cancer
24. Luteinizing hormone/human chorionic gonadotropin receptors in breast cancer
25. A mouse model to study the effects of hormone replacement therapy on normal mammary gland during menopause: Enhanced proliferative response to estrogen in late postmenopausal mice
26. Induction of mammary gland development in estrogen receptor-α knockout mice
27. Estrogen receptor null mice: What have we learned and where will they lead us?
28. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study
29. LHRH-agonist treatment in clinical and experimental human breast cancer
30. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials
31. Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors
32. Transgenic mice with chronically elevated luteinizing hormone are infertile due to anovulation, defects in uterine receptivity, and midgestation pregnancy failure
33. Elevated luteinizing hormone induces expression of its receptor and promotes steroidogenesis in the adrenal cortex
34. Elevated luteinizing hormone in prepubertal transgenic mice causes hyperandrogenemia, precocious puberty, and substantial ovarian pathology
35. Luteinizing hormone induction of ovarian tumors: Oligogenic differences between mouse strains dictates tumor disposition
36. Estradiol inhibits transcription of the human glycoprotein hormone α-subunit gene despite the absence of a high affinity binding site for estrogen receptor
37. Preparing mammary gland whole mounts from mice
38. Immunoperoxidase staining for estrogen and progesterone receptors in archival formalin fixed, paraffin embedded breast carcinomas after microwave antigen retrieval
39. Early exposure of the rat mammary gland to estrogen and progesterone blocks co-localization of estrogen receptor expression and proliferation
40. Mammary epithelial cells undergo secretory differentiation in cycling virgins but require pregnancy for the establishment of terminal differentiation
41. Adenohypophyseal hormones and their hypothalamic releasing factors
42. Effect of human chorionic gonadotropin on mammary gland differentiation and carcinogenesis
43. Chorionic gonadotropin inhibits rat mammary carcinogenesis through activation of programmed cell death
44. Structure of the lutropin/choriogonadotropin receptor
45. The presence of luteinizing hormone/human chorionic gonadotropin receptors in lactating rat mammary glands
46. Chronic hypersecretion of luteinizing hormone in transgenic mice selectively alters responsiveness of the α-subunit gene to gonadotropin-releasing hormone and estrogens
47. Transient increase in the risk of breast cancer after giving birth
48. Dual effect of parity on breast cancer risk
49. The mammary pathology of genetically engineered mice: The consensus report and recommendations from the Annapolis meeting
50. Hormones and mammary carcinogenesis in mice, rats, and humans: A unifying hypothesis
51. Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer
52. Prolactin receptor does not correlate with oestrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results of the Naples adjuvant (GUN) study
53. The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer
54. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer
55. Some endocrine characteristics of early menarche, a risk factor for breast cancer, are preserved into adulthood
56. Suppression by pregnancy of chemically induced preneoplastic cells of the rat mammary gland
57. N-nitroso-N-methylurea-induced mammary carcinogenesis: Effect of pregnancy on preneoplastic cells
58. Human chorionic gonadotropin and rat mammary cancer prevention
59. Does full-term pregnancy at a young age protect women against breast cancer through hCG?
60. Chemical carcinogen-induced tumorigenesis in parous, involuted mouse mammary glands
61. Lactation and breast cancer risk
62. Lactation and breast cancer risk: A case-control study in Connecticut
63. Lactation reduces breast cancer risk in Shandong Province, China
64. Lactation and the risk of breast cancer
65. Prevention of mammary carcinogenesis in rats by pregnancy: Effect of full-term and interrupted pregnancy
66. Induction of mammary adenocarcinomas by medroxyprogesterone acetate in BALB/c female mice
67. Ectopic pituitary grafts in mice: Hormone levels, effects on fertility, and the development of adenomyosis uteri, prolactinomas, and mammary carcinomas
68. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene
69. Progression of rat mammary development with age and its relationship to carcinogenesis by a chemical carcinogen